Aldeyra appoints Michael Alfieri as principal financial officer, Bruce Greenberg steps down

Aldeyra Therapeutics, Inc.

Michael Alfieri appointed as principal financial officer and principal accounting officer, effective Aug 31, 2024, via consulting agreement with Danforth Global, Inc.
Bruce Greenberg stepped down from positions including SVP Finance, Interim CFO, and principal accounting officer as of Aug 31, 2024.
Greenberg receives separation: six months base salary, lump-sum $125,895, and COBRA premium payments for up to six months.
Greenberg will provide consulting services through Nov 30, 2024, with continued vesting of outstanding stock options.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Alfieri

principal financial officer and principal accounting officer

ALDX · Aldeyra Therapeutics, Inc.

Effective: 2024-08-31
Filed: September 3, 2024, 7:59 PM ET

On August 29, 2024, the board of directors of Aldeyra Therapeutics, Inc. (the “Company”) approved the appointment of Michael Alfieri as the Company’s principal financial officer and principal accounting officer effective as of August 31, 2024 (the “Effective Date”).

Departed (interim)

Bruce Greenberg

Senior Vice President of Finance, Interim Chief Financial Officer

ALDX · Aldeyra Therapeutics, Inc.

Effective: 2024-08-31
Successor: Michael Alfieri
Filed: September 3, 2024, 7:59 PM ET

As previously disclosed by the Company, Bruce Greenberg stepped down from his positions with the Company, including as the Company’s Senior Vice President of Finance, Interim Chief Financial Officer and principal financial officer and principal accounting officer as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Alfieri was appointed as principal financial officer and principal accounting officer at Aldeyra Therapeutics, Inc..

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

On August 29, 2024, the board of directors of Aldeyra Therapeutics, Inc. (the “Company”) approved the appointment of Michael Alfieri as the Company’s principal financial officer and principal accounting officer effective as of August 31, 2024 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bruce Greenberg departed as Senior Vice President of Finance, Interim Chief Financial Officer at Aldeyra Therapeutics, Inc..

Action: stepped down
Role: Senior Vice President of Finance, Interim Chief Financial Officer

Exact text from the filing

As previously disclosed by the Company, Bruce Greenberg stepped down from his positions with the Company, including as the Company’s Senior Vice President of Finance, Interim Chief Financial Officer and principal financial officer and principal accounting officer as of the Effective Date.

View on SEC.gov

Aldeyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-211645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.